Kendall Morrison

Dr. Kendall Morrison is Chief Science Officer.

Dr. Morrison is a noted expert in antibody development and biotechnology, most recently serving as Senior Director, Protein Technologies at Agensys, Inc. (an affiliate of Astellas Pharma Inc. Japan) where he led a team of 28 scientists (working in Biology and Medicinal Chemistry) in the discovery and development of novel antibody-based therapies.

He has over 30 years of experience developing breakthrough technologies for the treatment, diagnosis and study of immunological and oncological conditions. He has led teams that developed target validation and discovery reagents; pre-clinical and clinical drugs, including Antibody Drug Conjugates (ADC) and ADC payloads, with five significant ADCs currently in clinical trials. He also played a significant role in the development of Certolizumab pegol (trade name Cimzia), which is currently approved for the treatment of Crohn’s disease, rheumatoid arthritis psoriatic arthritis and ankylosing spondylitis.

Dr. Morrison is listed as an inventor in 56 issued patents in the United States, with 79 patent filings and 185 total patent citations. He is a member of the British Society of Immunology and has published influential papers in Molecular Cancer Therapeutics, Cancer Research, the American Journal of Pathology, Journal of Clinical Pathology and more.

He holds a combined B.S. with honors in Microbiology and Immunology from the University of West Scotland, UK; and a Ph.D. in Pathology and Molecular Biology from the Medical School at the University of Southampton, UK.